SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how these conditions, which include developmental delay, intellectual disability, neuromuscular disorders, reproductive disorders, birth defects and other so-called rare diseases, present unique challenges to the cytogenetics and molecular pathology teams investigating th ...

Company Overview - Black Diamond (BDTX) is part of the Medical sector, which includes 932 companies and ranks 8 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for BDTX's full-year earnings has increased by 39.2%, reflecting improved analyst sentiment [4] - Year-to-date, Black Diamond has returned 9.1%, outperforming the Medical sector's average return of 8.3% [4] Industry Context - Black Diamond operates within the Medical - Biomedical and Genetics industry, which consists of 453 stocks and ranks 88 in the Zacks Industry Rank [6] - The average return for stocks in this industry is 21.9% this year, indicating that BDTX is slightly underperforming compared to its industry peers [6] Comparative Analysis - Bionano Genomics, Inc. (BNGO) is another Medical stock that has shown strong performance, with a year-to-date return of 9.2% and a consensus EPS estimate increase of 46.2% over the past three months [5] - Both Black Diamond and Bionano Genomics are noteworthy for investors interested in the Medical sector due to their solid performance [7]

Core Insights - iBio, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -57.14% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, consistent with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - iBio shares have declined approximately 49.4% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Company Performance - Over the last four quarters, iBio has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $0.1 million, and for the current fiscal year, it is -$0.40 on revenues of $0.5 million [7] - The estimate revisions trend for iBio was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which iBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Keros Therapeutics reported a quarterly loss of $0.18 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.11, representing an earnings surprise of +83.78% [1] - The company posted revenues of $14.26 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 86.04%, compared to revenues of $0.39 million in the same quarter last year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.11 on revenues of $7.67 million, while for the current fiscal year, the estimate is $0.33 on revenues of $235.61 million [7] - The estimate revisions trend for Keros Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - Keros Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Keros Therapeutics' stock may be influenced by the overall industry outlook, as the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Exelixis reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.68 per share, and showing an increase from $0.47 per share a year ago, resulting in an earnings surprise of +14.71% [1] - The company achieved revenues of $597.76 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.49%, and up from $539.54 million year-over-year [2] - Exelixis has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 14.3% since the beginning of the year, while the S&P 500 has increased by 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $609.17 million, and for the current fiscal year, it is $2.69 on revenues of $2.32 billion [7] - The Medical - Biomedical and Genetics industry, to which Exelixis belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Group 1 - Bionano Genomics, Inc. has launched a public offering of 5 million shares at a price of $2.00 per share, aiming to generate $10 million in gross proceeds, with potential additional funds of $20 million if warrants are fully exercised [1][2] - The funds from the offering are intended to support general corporate needs and will provide a solid foundation for the company's expansion into clinical and anatomic pathology [2][3] - The company is focusing on enhancing utilization among routine users, strengthening its installed base, accelerating adoption of its VIA software, and developing reimbursement support for its optical genome mapping (OGM) technology [3][4] Group 2 - Bionano Genomics, Inc. is based in San Diego, California, and specializes in genome analysis solutions, aiming to transform the understanding of the genome since its founding in 2003 [4]

Core Insights - Several biotech companies experienced significant after-hours stock gains due to clinical trial updates, funding announcements, and upcoming product showcases Group 1: Prime Medicine Inc. (PRME) - Shares rose 8.14% in after-hours trading, reaching $5.05 after a regular session close of $4.67, which was up 16.46% [2] - The company reported a narrowed net loss of $52.6 million or $0.41 per share on revenue of $1.12 million, highlighting early clinical data from its CGD program [3] - Upcoming catalysts include planned IND filings for Wilson's Disease and Alpha-1 Antitrypsin Deficiency in 2026, with initial clinical data expected in 2027 [4] Group 2: Meihua International Medical Technologies Co. Ltd. (MHUA) - Shares increased by 7.55% in after-hours trading, reaching $0.4444 after a regular session close of $0.4132, which was down 2.62% [4] - The company is set to report its quarterly earnings on September 18, 2025 [5] Group 3: Elutia Inc. (ELUT) - Shares rose 10.17% in after-hours trading, reaching $1.30 after closing at $1.18, which was down 3.28% [5] - Elutia announced clinical data showing its biologic envelopes significantly ease reoperations for cardiac implantable electronic devices, reducing procedural difficulty by over 40% [6] - The company will exhibit its EluPro antibiotic-eluting BioEnvelope at the Vizient Innovative Technology Exchange on September 17, 2025 [6] Group 4: Aligos Therapeutics Inc. (ALGS) - Shares increased by 2.79% in after-hours trading, reaching $9.20 after closing at $8.95, which was down 4.48% [7] - Aligos presented six preclinical studies at the 2025 International HBV Meeting, including new data on its capsid assembly modulator and a novel ASO strategy targeting hepatitis delta virus [8] - Upcoming catalysts include continued enrollment and data updates from the B-SUPREME study and a scheduled earnings report on November 5, 2025 [9] Group 5: Bionano Genomics Inc. (BNGO) - Shares fell 35.74% to $1.78 before rebounding 6.74% in after-hours trading to $1.90 [10] - The decline followed a $10 million public offering priced at $2.00 per share, expected to close around September 17, 2025 [11] - Bionano plans to use the funds for working capital and general corporate purposes, with recent publications highlighting the utility of its Optical Genome Mapping in cancer biomarker analysis [11] Group 6: Cognition Therapeutics Inc. (CGTX) - Shares climbed 6.21% in after-hours trading, reaching $1.71 after closing at $1.61, which was up 4.55% [12] - The company’s lead candidate, zervimesine, reached 75% enrollment in its Phase 2 START study for early Alzheimer's disease, backed by the National Institute on Aging [13] - Cognition recently closed a $30 million registered direct offering to support Phase 3 development [13]

Market Overview - The market has experienced significant shifts, with several companies facing notable price declines due to sector-specific challenges and broader economic conditions [1] REX American Resources Corporation - REX American Resources Corporation's stock price has dropped over 50% to $30.54, facing potential operational challenges and broader market conditions affecting the Basic Materials sector [2] - The company's recent announcement regarding the conversion of REX-Osprey™ SOL + Staking ETF to a Regulated Investment Company structure may be a strategic move to enhance investor returns, but it may not have an immediate impact on REX's stock performance [2] Charles & Colvard, Ltd. - Charles & Colvard, Ltd. has seen a 42.65% decrease in its stock price to $0.43, facing challenges in the Luxury Goods and Consumer Cyclical sector [3] - The company's delisting from Nasdaq marks a significant change in its trading status, potentially contributing to the stock's decline [3] Bionano Genomics, Inc. - Bionano Genomics, Inc. experienced a 38.81% decline in its stock price to $1.69, specializing in genome analysis solutions [4] - Despite showcasing the utility of optical genome mapping in cancer biomarker analysis, market sentiment towards biotech investments and specific operational news may have contributed to the price drop [4] Osisko Development Corp. Warrant - Osisko Development Corp. Warrant saw a 32.43% decline to $0.25, with price movements influenced by fluctuations in gold prices and investor sentiment towards the Basic Materials sector [5] BT Brands, Inc. - BT Brands, Inc. experienced a 31.36% decline in its stock price to $0.31, operating in the quick-service restaurant industry [6] - The company faces challenges in the Consumer Cyclical sector, with market competition and broader economic factors affecting consumer spending potentially contributing to the stock's decline [6] Conclusion - The movements in these companies underscore the volatility and diverse factors influencing the market, with investors and analysts likely to monitor these developments for insights into the underlying causes of price changes and their potential long-term implications [7]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 150 points, down 0.37% to 45,713.02 [1] - NASDAQ fell 0.03% to 22,341.05, and S&P 500 dropped 0.14% to 6,605.77 [1] - Energy shares increased by 1.1%, while utilities stocks fell by 0.8% [1] Company Performance - Dave & Buster's Entertainment Inc. reported second-quarter revenue of $557.41 million, missing analyst estimates of $562.78 million [2] - Adjusted earnings for Dave & Buster's were 40 cents per share, below estimates of 92 cents per share [2] Commodities - Oil prices increased by 2.2% to $64.70, while gold rose by 0.2% to $3,726.00 [5] - Silver traded up 0.1% to $43.000, and copper fell 0.1% to $4.7120 [5] European Markets - European shares were lower, with the eurozone's STOXX 600 falling 0.86% [6] - Spain's IBEX 35 Index decreased by 1.30%, and London's FTSE 100 fell 0.74% [6] Asian Markets - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [7] Notable Stock Movements - Turbo Energy, S.A. shares surged 408% to $13.72 after securing a $53 million contract for energy storage projects in Spain [8] - WEBTOON Entertainment Inc. shares rose 28% to $19.13 following a non-binding agreement with Disney [8] - Jumia Technologies AG shares increased by 22% to $11.90 after an upgrade from RBC Capital [8] - Bionano Genomics, Inc. shares dropped 41% to $1.6398 due to a $10 million public offering announcement [8] - GD Culture Group Limited shares fell 19% to $7.84 after entering a share exchange agreement [8] - Next Technology Holding Inc. shares decreased by 17% to $23.79 after filing for a stock shelf of up to $500 million [8] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [11] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [11] - U.S. industrial production rose by 0.1% in August, exceeding market expectations [11] - U.S. retail sales increased by 0.6% month-over-month in August, surpassing expectations [11] - Export and import prices both rose by 0.3% in August [11]

U.S. Stock Market - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points, down 0.29% to 45,751.36 [1] - The NASDAQ fell 0.01% to 22,349.18, and the S&P 500 dropped 0.05% to 6,612.17 [1] - Energy shares increased by 1.2%, while utilities stocks fell by 0.7% [1] Retail Sales - U.S. retail sales rose 0.6% month-over-month in August, matching the revised 0.6% gain in July and exceeding market expectations of a 0.2% gain [2][10] Commodities - Oil prices increased by 1.4% to $64.16, while gold rose by 0.5% to $3,737.00 [3] - Silver traded up 0.7% to $43.240, and copper fell by 0.2% to $4.7105 [3] European Markets - European shares were lower, with the eurozone's STOXX 600 falling 0.8% and Spain's IBEX 35 Index down 1.1% [4] - London's FTSE 100 decreased by 0.7%, Germany's DAX 40 dipped 1.2%, and France's CAC 40 fell 0.7% [4] Asian Markets - Asian markets closed mostly higher, with Japan's Nikkei gaining 0.30% and India's BSE Sensex increasing by 0.73% [5] Company Performance - Turbo Energy, S.A. shares surged 534% to $17.73 after securing a $53 million contract for energy storage projects in Spain [7] - FGI Industries Ltd. shares rose 113% to $8.46, while Brera Holdings PLC shares increased by 109% to $14.30 [7] - Bionano Genomics, Inc. shares dropped 41% to $1.6292 following a $10 million public offering announcement [7] - GD Culture Group Limited shares fell 28% to $7.00 after entering a share exchange agreement for Bitcoin assets [7] - Chijet Motor Company, Inc. shares decreased by 26% to $0.0848 [7] Economic Indicators - U.S. business inventories increased by 0.2% month-over-month in July, aligning with market estimates [8] - The NAHB/Wells Fargo Housing Market Index remained steady at 32 in September [8] - U.S. industrial production rose by 0.1% in August, following a 0.4% decline in the previous month [8]